Respiratory syncytial virus mRNA vaccine study results.
In June 2024, the U.S. Food and Drug Administration (FDA) approved Moderna's mRESVIA vaccine against respiratory syncytial virus (RSV). respiratory syncytial virus (RSV), which causes bronchiolitis. bronchiolitis.
Equipo Ciencia was one of the sites where this study was conducted to evaluate the safety and efficacy of mRNA-1345, an mRNA vaccine intended to protect adults over 60 years of age against this disease by preventing the first episode of acute lower respiratory infection with RSV within 14 days and up to one year after injection. The study began in November 2021 and concluded in October 2024.
Globally, 36,814 volunteers were included, of whom 2102 participated at our center. Most adverse effects were mild to moderate, and resolved within 24 to 48 hours of symptom onset.
The vaccine was effective against RSV respiratory infection in all subgroups, regardless of age, sex, risk factors, comorbidities, geographic region, and socioeconomic status.
A single dose of vaccine showed 83.7% efficacy against lower respiratory tract disease (LRTI) in healthy persons with at least 2 signs or symptoms.
This is the first mRNA vaccine to be approved for a disease other than Covid-19 (mRNA-based vaccine against RSV prefusion glycoprotein F).
Moderna's vaccine is added as another strategy to vaccinate older adults against RSV. Of the three vaccines currently on the market to prevent diseases caused by this virus, Equipo Ciencia participated in three studies: two for adults over 60 years of age and one for pregnant women, which is currently included in the national vaccination schedule.
